$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
April 11, 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its...
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
July 27, 2020 09:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that an investigator initiated study, authored by Dr. Samir...
Endonovo Therapeutics Announces Issuance of U.S. Patent Covering Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke
January 07, 2020 08:30 ET
|
Endonovo Therapeutics, Inc.
Issuance of U.S. Patent No. 15217855 Further Bolsters Endonovo’s Intellectual Patent Portfolio Los Angeles, CA, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD /...
Endonovo Therapeutics Provides SofPulse® To All NFL Teams [Updated]
December 23, 2019 09:48 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD) ("Endonovo" or the "Company"), announced today the delivery of SofPulse® evaluation units to all...
Endonovo Therapeutics Provides SofPulse® To All NFL Teams
December 23, 2019 08:30 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today the delivery of SofPulse® evaluation units to all...
Endonovo Therapeutics Appoints Dr. Geoffrey Abrams of Stanford University to Its Scientific Advisory Board
August 30, 2019 09:00 ET
|
Endonovo Therapeutics Inc.
LOS ANGELES, Aug. 30, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Endonovo Therapeutics Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical®...
Endonovo Therapeutics Appoints Dr. Roc Alan McCarthy as a Scientific Advisory Board Member
May 09, 2019 09:20 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA , May 09, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, that Roc Alan McCarthy, D.O. will be joining the company as a Scientific Advisory Board...
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing
May 07, 2019 09:20 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 07, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his position,...
Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
December 18, 2018 09:25 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies...
Endonovo Expands SofPulse Commercialization
December 13, 2018 09:20 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies,...